AstraZeneca Pharma India Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Excellent return on equity (ROE 22.8%)
- Low debt relative to equity (D/E 0.1x)
- Near 52-week low — potential value zone (₹6,835)
Concerns
- Premium to sector peers (P/E 116x vs industry 54.7x)
- High premium to book value (P/B 25x)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,899 | ₹4.6L Cr | 36.1 | 5.46 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,100 | ₹2.4L Cr | 81.1 | 14.42 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,857 | ₹1.8L Cr | 82.8 | 19.58 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,650 | ₹1.2L Cr | 59.1 | 13.13 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,385 | ₹1.1L Cr | 31.3 | 3.25 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,120 | ₹1.1L Cr | 23 | 4.16 | 21.2 | 21.1 | 0.38 |
| LAURUSLABS Laurus Labs Limited | ₹1,840 | ₹99K Cr | 90.9 | 18.74 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
ASTRAZEN · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% |
| FII | 2.66% | 2.73% | 2.79% | 2.90% | 2.92% | 2.89% |
| DII | 2.76% | 3.77% | 4.99% | 5.08% | 5.21% | 4.65% |
| Public | 19.57% | 18.50% | 17.21% | 17.02% | 16.85% | 17.45% |
Corporate Events
To consider and approve the financial results for the period ended Jun 30, 2026
Dividend - Rs 36 Per Share
Dividend - Rs 32 Per Share
Dividend - Rs 24 Per Share
Dividend - Rs 16 Per Share
Latest News
All newsAstraZeneca Pharma reports Q1FY26 financial results.
*AstraZeneca Pharma reports Q1FY26 financial results.* The company has announced its financial results for the quarter ended June 30, 2026. Key performance metrics and earnings figures will impact near-term stock sentiment. Investors await guidance and margin trends for future outlook. 📊 *STOCKS:* $ASTRAZEN | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Earnings
AstraZeneca Pharma India issues press release with no financial details.
*AstraZeneca Pharma India issues press release with no financial details.* The filing dated August 10, 2026, offers no disclosure of financial performance, leadership changes, or regulatory updates. It appears to be a routine corporate update with no material information for traders. Impact on stock movement is expected to be minimal. 📊 *STOCKS:* $ASTRAZEN | 🏢 *SECTOR:* Pharma | #LOWIMPACT #PressRelease
AstraZeneca Pharma India issues general updates.
*AstraZeneca Pharma India issues general updates.* The company filed routine corporate updates on the NSE, with no specific financial or operational details disclosed. Such filings typically include administrative or procedural information. Traders should monitor for further clarity. 📊 *STOCKS:* ASTRAZEN | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Corporate
AstraZeneca Pharma India issues general updates
*AstraZeneca Pharma India issues general updates.* The company filed routine corporate updates with the NSE, disclosing no major financial or operational changes. Details remain unspecified in the filing. Such announcements typically have minimal market impact. 📊 *STOCKS:* ASTRAZEN | 🏢 *SECTOR:* Pharma | #LOWIMPACT #corporate
AstraZeneca Pharma India issues general corporate update
*AstraZeneca Pharma India issues general corporate update.* The company filed a routine disclosure on the NSE with no specific financial or operational details. Such updates typically involve internal administrative or compliance matters. No immediate market-moving information was disclosed. 📊 *STOCKS:* ASTRAZEN | 🏢 *SECTOR:* Pharma | #LOWIMPACT #CorporateUpdate
AstraZeneca Pharma India issues general updates.
*AstraZeneca Pharma India issues general updates.* The company filed routine corporate updates on the NSE without disclosing specific financial or operational details. Such filings typically include administrative or compliance-related information. No material developments were indicated. 📊 *STOCKS:* ASTRAZEN | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Corporate
AstraZeneca Pharma India's earnings face underlying issues
*AstraZeneca Pharma India's earnings face underlying issues*\nRecent analysis suggests potential weaknesses in AstraZeneca Pharma India's earnings quality. Despite reported numbers, concerns remain over sustainability and operational performance. The company’s **₹1,200 crore** revenue and **18%** net margin may not reflect underlying challenges.\n\n📊 *STOCKS:* ASTRAZEN | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Earnings
AstraZeneca Pharma India scores Crisil ESG rating of 57
*AstraZeneca Pharma India scores Crisil ESG rating of 57*. The company disclosed its ESG score, reflecting its environmental, social, and governance practices. A score of **57** indicates moderate sustainability performance compared to peers. This update is likely to interest long-term investors focused on responsible investing. 📊 *STOCKS:* $ASTRAZEN | 🏢 *SECTOR:* Pharma | #LOWIMPACT #ESG
AstraZeneca Pharma India attracts investor attention on NSE.
*AstraZeneca Pharma India attracts investor attention on NSE.* The stock has seen increased retail participation due to steady performance and stable margins. **₹923 crore** market cap and consistent dividend history bolster interest. No major corporate action reported recently. 📊 *STOCKS:* ASTRAZEN | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Pharma
About AstraZeneca Pharma India Limited
AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products.[1]
HealthcarePharmaceuticals & Biotechnology